Compositions and Methods for Treating Eyes and Methods of Preparation

Abstract

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and / or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

Description

PRIORITY NOTICE[0001]The present application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Serial No. 62 / 501,390 filed on May 4, 2017; to U.S. Provisional Patent Application Serial No. 62 / 621,299 filed on Jan. 24, 2018; and to U.S. Provisional Patent Application Serial No. 62 / 646,287 filed on Mar. 21, 2018, the disclosures of which are incorporated herein by reference in their entirety.TECHNICAL FIELD OF THE INVENTION[0002]The present invention relates to compositions for treating eyes, methods for treating eyes, and methods for preparing said compositions and more specifically to treating the eyes for glaucoma, for post-op care after various eye surgeries, and / or for dry eyes.COPYRIGHT AND TRADEMARK NOTICE[0003]A portion of the disclosure of this patent application may contain material that is subject to copyright protection. The owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it ap...

AI Technical Summary

Benefits of technology

The present invention provides pharmaceutical compositions and methods for treating eyes that have several technical effects. Firstly, the compositions result in increased patient compliance, meaning that fewer treatments or separate medications are needed. Secondly, the compositions result in improved efficacy, meaning that they are more effective in treating the eyes. Thirdly, the compositions result in minimal side-effects, meaning that they cause fewer side-effects in the patient. Finally, the compositions result in minimal or better cost savings for the patient, meaning that they require fewer separate medications to be administered to the eyes.

Problems solved by technology

Typical treatments for such eye problems include treatments, via eye drops and / or intra-cameral injections, of a variety of different packaged medications, typically each with one given API (active pharmaceutical ingredient), which may result in patient compliance problems because the patient needs to use multiple eye droppers for a given dosing (or multiple injections for a given dosing), and increased patient cost problems.

Images